Table 1.
Baseline patient and disease characteristics.
| Radotinib 300 mg BID (n = 79) | Radotinib 400 mg BID (n = 81) | Imatinib 400 mg QD (n = 81) | |
|---|---|---|---|
| Age, years | |||
| Median | 45 | 43 | 45 |
| Range | 20–75 | 18–84 | 18–83 |
| Sex, n (%) | |||
| Male | 52 (66) | 47 (58) | 50 (62) |
| Female | 27 (34) | 34 (42) | 31 (38) |
| Weight, kg | |||
| Median | 61 | 60 | 62 |
| Range | 43–100 | 40–96 | 41–96 |
| ECOG performance status, n (%) | |||
| 0 | 53 (67) | 55 (68) | 51 (63) |
| 1 | 26 (33) | 25 (31) | 29 (36) |
| 2 | 0 | 1 (1) | 1 (1) |
| Additional chromosomal abnormalities, n (%) | 6 (8) | 7 (9) | 6 (7) |
| Type of BCR‐ABL1 transcript | |||
| e13a2 ± e14a2 | 78 | 80 | 80 |
| Others | 1 | 1 | 1 |
| Sokal risk, n (%) | |||
| Low | 21 (27) | 22 (27) | 22 (27) |
| Intermediate | 38 (48) | 38 (47) | 39 (48) |
| High | 20 (25) | 21 (26) | 20 (25) |
| Duration of CML, days | |||
| Median | 22 | 23 | 22 |
| Range | 7–102 | 7–66 | 6–71 |
| Prior treatment, n (%) | |||
| Hydroxycarbamide | 69 (87) | 70 (86) | 72 (89) |
| Anagrelide* | 5 (6) | 5 (6) | 8 (10) |
| Imatinib | 0 | 2 (2) | 2 (2) |
BID, twice daily; CML, chronic myeloid leukaemia; ECOG, Eastern Cooperative Oncology Group; QD, once daily.
*
All patients who were administered anagrelide also received hydroxycarbamide.